DUBLIN--(BUSINESS WIRE)--The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018" report has been added to ResearchAndMarkets.com's offering.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2012 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
- Trends in preclinical stage dealmaking in the biopharma industry since 2012
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,000 preclinical stage deals
- The leading preclinical stage deals by value since 2012
- Most active preclinical stage dealmakers since 2012
- The leading preclinical stage partnering resources
Available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Why do companies partner preclinical stage compounds?
Chapter 3 - Preclinical stage deal strategies and structure
Chapter 4 - Preclinical stage partnering payment strategies
Chapter 5 - Trends in preclinical stage deal making
Chapter 6 - Payment terms for preclinical stage partnering
Chapter 7 - Leading preclinical stage deals
Chapter 8 - Top 50 most active preclinical stage dealmakers
Chapter 9 - Preclinical stage partnering contracts directory
Chapter 10 - Preclinical stage deal making by development stage
For more information about this report visit https://www.researchandmarkets.com/research/ctbnzs/global?w=4